Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report

Rao, Reena; Majlessipour, Fataneh; Ziring, David; Baca, Nicole

doi:10.1089/jayao.2020.0077

Cited by 2 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The leukemogenic mechanism of azathioprine is considered to involve prevention of repair of drug-induced DNA double-strand breaks [18], and induction of mismatch repair (MMR) deficiency, as reflected by microsatellite instability [19,20]. On the other hand, conventional treatments and biologics, including anti-TNF-α antagonists and ustekinumab, reportedly only have a slight association with myeloid neoplasms in patients with IBD and other immune-mediated diseases [16,[21][22][23][24][25][26]. However, our patient developed APL even though he had not received thiopurines.…”

Section: Discussionmentioning

confidence: 99%

Acute Promyelocytic Leukemia in a Patient With Chronic Continuous Type of Crohn’s Disease

et al. 2022

View full text Add to dashboard Cite

Chronic inflammation can induce leukemogenic mutations in hematopoietic stem cells (HSCs). We report a case of acute promyelocytic leukemia (APL) in a patient with chronic continuous type of Crohn's disease. The patient had been diagnosed with Crohn's disease at the age of 28 years and had received conventional treatments with biologics, but not azathioprine. At the age of 51, he was diagnosed with APL with ider(17). Long-term exposure to chronic continuous inflammation from Crohn's disease might be a factor inducing genomic instability in HSCs, which lead to the subsequent development of APL. APL is a rare hematological manifestation that required attention in Crohn's disease patients.

show abstract